The effects of recombinant human growth hormone on cardiopulmonary function in elective abdominal aortic aneurysm repair  by Barry, M.C. et al.
Eur l Vasc Endovasc Surg 16, 311-319 (1998) 
The Effects of Recombinant Human Growth Hormone on 
Cardiopulmonary Function in Elective Abdominal Aortic 
Aneurysm Repair 
M. C. Barry*, K. Mealy, S. J. Sheehan, P. E. Burke, A. J. Cunningham 1, A. Leahy and 
D. Bouchier Hayes 
Departments of Surgery and Anaesthesia I, Royal College of Surgeons m Ireland and Beaumont Hospital, 
Dubhn, Ireland 
Objectives: cardzorespIratory comphcatzons are the predonunant source of morbzdzty zn patients undergoing major 
surgen d Recombinant human growth hormone (rhGH) has prevzously been shown to be effective zn zmprovlng respiratory 
and car&ac yqlnctzon I  compronnsed patients. 
Design: the amz of thzs study was to assess the effects of perloperatwe rhGH on car&ac functzon in 33 patzents undergoing 
electzve znfrarenaI abdominal aortic aneu~ ysm repazr. 
Methods: pattents were randonused to one of three groups placebo for 6 days before and after surgery (control, n = 12); 
genotropin (GH) 0.3 umts/kg/day for 6 days before and after surgery (pre and postop GH, n= lO) and placebo for 6 days 
before and GH (0 3 units/kg/day) for 6 days after surgery (postop EH, n= 11) Patzents were assessed on days 7 and 1 
before and days 7, 14 and 50 after operatzon. Intraoperatzve cardiac zndex (CI) was measured after mductzon of anaesthesia, 
before and after aortw cross-clamping, after aortic unclampmg and at the end of surgery. 
Results: pretreatment wzth GH resulted zn a szgnzficantly hzgher heart rate during surgery and was assoczated wzth a 
trend towards h~gher car&ac index (CI) (p<0.067) at all stages of surgery Mean arterzal blood pressure at the stage of 
aortzc unclampzng was szgn~cantly hzgher in patzents treated with GH preoperatzvely. 
Conclusions: larger studzes are requzred to evaluate the bene]ic~al effects of GH zn aortzc surgery. However, data from 
this pdot study suggests that perzoperatzve GH admmzstratzon may result tn zmproved cardzac pelformance durzng aortzc 
surgery 
Introduction human volunteers, urgical patients undergoing major 
surgery and critically ill pahents, by decreasing skeletal 
Cardiorespiratory complications remain the main muscle proteolysis, promoting protein synthesis and 
source of morbidity and mortality in elective aortic increasing lipolysis. 5~ Recombinant human growth 
surgery. 1'2 Cardiorespiratory dysfunction following hormone has been shown to prevent he deterioration 
elective aortic aneurysm surgery is multifactonal, re- in skeletal muscle function which accompanies major 
suiting in part from intrinsic disease as well as the elective surgery. 5 Furthermore, GH has been shown to 
metabolic and physiological responses to surgical improve myocardial contrachlity and cardiac output 
trauma. One of the major sources of cardiac morbidity in healthy volunteers. 1°
associated with AAA surgery is due to the increased The aim of this study was to test the hypothesis 
myocardial workload provoked by the profound that perioperative treatment with GH would improve 
haemodynamic changes associated with aortic clamp- intraoperative haemodynamic responses to aortic 
ing and declamping. 3"4 Optimisation of preoperative clamping and unclampmg and mtraoperahve gas ex- 
cardiopulmonary function would be of enormous change during elective abdominal aorhc surgery. 
benefit in this group of patients. 
Recombinant human growth hormone (GH) has 
been shown to induce positive nitrogen balance in Methods 
Patzents 
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and verbal mformation about the nature of the study for 24 h postoperatively. The following variables were 
and their written informed consent was obtained. The monitored on-line: heart rate (HR), mean arterial blood 
study group comprised patients undergoing elective pressure (MABP), central venous pressure (CVP), pul- 
abdominal aortic aneurysm repair. Exclusion criteria monary arterial wedge pressure (PAWP) and mean 
included immunosuppresslon, malignancy, type 1 &a- pulmonary artery pressure (MPAP). Cardiac output 
betes mellitus, hepatic or renal impairment, steroid (CO) values were obtained in triplicate by thermo- 
ingestion or surgery within the previous month. Pre- dilution. Cardiac index (CI), stroke volume index (SVI), 
operative cardiac ejection fraction was assessed using systemic vascular resistance (SVRI), and pulmonary 
echocar&ography before entry into the study, vascular esistance (PVRI), were derived from stand- 
ard formulae. Rate pressure product (RPP) was cal- 
culated from the product of systohc blood pressure 
and heart rate. This measurement correlates with myo- 
Protocol cardial oxygen consumption. 11 
This was a double-blind placebo controlled study 
using GH (Genotropin, Pharmacia Ltd Sweden). Intraoperatzve gas exchange. Mixed venous and arterial 
' blood samples were taken simultaneously following 
Patients were randomised to one of three treatment 
groups. Control: treatment with placebo for 6 days induction of anaesthesia, before and after aortic cross- 
before and after surgery; pre and postop: treatment clamping, immediately before and after unclamping 
with GH for 6 days before and after surgery; postop: and at the end of surgery. The following variables 
were calculated off-line from the measured variables 
treatment with placebo for 6 days before and GH for as follows" arterial blood oxygen content (CaO2 (ml/ 
6 days after surgery. The dose of GH was 0.3 IU/kg/  dl)) = 1.39 x Hb x SaO, (Hb = haemoglobin in g/dl; 
day administered subcutaneously at 08 00 daily. The 
placebo vials contained the same vehicle as the GH SaOa= arterial blood oxygen saturation (%)); mixed 
vials and were visually indistinguishable Patients re- venous blood oxygen content (CvO2) = 
ceived a normal ward diet for the duration of the 1.39 x Hb x SvO2 (SvO2=venous blood oxygen sat- 
study. Patients were fasted for 8 h before surgery and uratlon (%)); total oxygen delivery (DO2 (ml/min/ 
diet was reintroduced when clinically appropriate, m2)) =CO x CaO2 (CO=cardiac output (litres)); total 
oxygen consumption (VO2 (ml/min/m2)) = 
generally 72 h postoperattvely. CO x (CaO, - CvO~). 
Pre and postoperative clinzcal mvestigatwns 
StatLstzcal nalysis 
Vital signs. Blood pressure, pulse, respiratory rate and 
temperature were assessed aily following entry into Results are expressed as mean+s.E.M, in text and 
the study, figures. Statistical analysis was carried out using two 
way analysis of variance for comparison of multiple 
Hormone levels. Venous blood was taken daily in the means with posthoc Scheffe test analysis for repeated 
morning before rejection of GH or placebo for de- comparisons. Significance was accepted for p<0.05. 
termination of plasma levels of growth hormone (GH) Statistical analysis was carried out using the software 
and insulin-like growth factor-1 (IGF-1)on days -7  Statvmw 513 +TM (Brainpower Inc., Calabasas, Cah- 
and -1  before surgery and on days 7, 14 and 50 forma). 
postoperatively. GH was measured by fluo- 
rolmmunometnc assay using a commercially available 
kit (DELFIA-hGH, Wallac Oy, Finland). IGF-1 was 
measured by double antibody radioimmunoassays. Results 
Patwnts 
Intraoperatzve investzgatlons Thirty-three patients were included in the study. Eight 
patients failed to complete the study or breached the 
Cardiac function. Radial and pulmonary artery catheters protocol and were excluded. One patient was found 
were inserted following reduction of anaesthesia for to have suprarenal extension of the aneurysm and was 
haemodynamic monitoring throughout surgery and excluded from the study. Another patmnt developed 
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Table 1. Demographic details of patients included in this study. 
Control Pre and postop GH Postop GH 
Number 10 8 7 
Age (years) 72 7_+1 5 71 12_+2 71 57_+2 1
Sex Raho (M/F) 10M 6M/2F 6M/1F 
Preop APACHE II score 5 6 _+ 3 7 6 4 -t- 0 8 6 14 -+ 0 5 
Preop car&ac ejection (%) 51 2 -+ 3 7 52 1 -t- 5 1 54 6 -+ 2 7 
cholangitis on day - 1 and had her surgery postponed.  70 r 
Two further patients were deemed unfit for surgery 1 
fol lowing assessment of respiratory funchon. CT brain 60 
scan carried out on a patient with hemispherical  symp-  
toms revealed the presence of a recent infarct 50 -  
necessitating postponement  of surgery. The remaining 
three patients had their surgery postponed for 40 
logistical reasons. ,~, 
The 25 patients who completed the study were 
randomised as follows: control: n = 10; pre and postop: 30 
n=8;  postop'  n=7.  There were 22 males and three 
females. All groups were matched for age, body  mass 20 
index (BMI), preoperat ive cardiac function and 
APACHE 11 score (Table 1). 10 
0 
Day -7 Day -1 Day 7 Day 14 Day 60 
Vztal signs Day 
Fig. 1. Serum growth ormone levels measured inpatients treated 
There was no difference between groups in heart with placebo alone (control), GH pre and postoperahvely (preop 
rate, b lood pressure or respiratory rate throughout  the and postop) and patients treated with GH postoperatively only 
(postop) Data is shown as mean+s E M ([~) Control, (~) pre and 
durat ion of the s tudy postop, (©) postop *p=0 005 vs preop and postop 
80O 
Hormone levels 
There was no significant change in p lasma GH or IGF- 
1 levels dur ing the 6 day preoperat ive per iod in the 600 - 
placebo group or postop GH groups (Figs 1 and 2). 
However ,  6 days '  treatment with GH resulted in a 
significant increase (pre and postop 52.6 + 20 mU/1) in ~ 
GH levels on day 1 compared  to the other two "~ 400 
groups (control: 0.889 + 0.26; postop: 0.34-t- 0.16 p = 
0.005 vs. preop and postop ANOVA). There was a 
similar s igmhcant  increase in IGF-1 levels at day -1  
(643 + 110ng/ml )  compared to the other two groups 200 
(control: 99 _+ 13; postop: 147_+ 22 p = 0.0001 ANOVA). 
This increase in IGF-1 and GH levels in the pretreated 
group was sustained into the postoperahve per iod I I I I I 
GH and IGF-1 levels remained elevated on day 7 0 Day-7 Day-1 Day 7 Day 14 Day 60 
postoperat ively (GH: 3.85+0.7 p=0 039 vs. control; Day 
IGF-I:  238 _+ 58 p = 0 0012 vs. control). There was a less 
marked but  stahshcal ly significant increase in GH Fig. 2. Serum msuhn-hke growth factor i (IGF-1) levels before and 
after elective AAA surgery IGF-1 levels are represented on the y- 
and IGF-1 levels in the postop group on day 7 (GH: axis as ng/ml Data is presented as mean+s E M Key as for Fig 1 
19.14 + 9.4; IGF: 232 -t- 41). Hormone levels in this group *p = 0 0001 vs control and postop 
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had returned to normal levels by day 14 post- 110- 
operahvely. 
100 
Intraoperative clinical investlgatwns 90 * * 
For the purposes of the intraoperative data analysis, 
patients are divided into two groups: control (includes ~ 80 
control patients and pahents treated with GH in the 
postoperative period only) and preop and postop 70 
(patients treated with GH preolSeratively). Duration 
of anaesthesia, surgery and aorhc cross clamp time 
were similar in both groups. Blood loss, intravenous 60 
fluid and transfusion requirements were also similar 
(Table 2). 50 I I I I I I I 
S J J d o°' 
"Ih_me 
There was a sigmficant difference m heart rate between 
the two study groups following aortic cross-clamping Fig. 3. Intraoperative h art rate in patients treated with placebo 
preoperatively (control) and patients treated wlth GH preoperatively 
which persisted to the end of surgery and 24 h post- (preop and postop) Time points hown on the x-axis and heart rate 
operatively (control' postinduction 67+4 beats/min; shown as beats/minute on the y-axis (E~) Control, (©) pre and 
post-clamp 78+5 beats/min; post-unclamp 68+3; postop *p=00214vs control 
preop and postop GH: postinduchon 72 + 4; postclamp 
83 _+ 6 (p = 0.013 vs. control); post-unclamp 82 + 5 (p = 
0.214 vs. control) (Fig. 3) This trend had not been was of a magnitude which we feel would be clinically 
noted during the 6 days before surgery, important. Stroke volume index (SVI) was similar in 
both groups at all stages of surgery as were left and 
right ventricular stroke work indices. No significant 
difference was seen in either systemic or pulmonary 
Cardzac functwn vascular esistance. Pulmonary artery wedge pressures 
and pulmonary artery pressures were similar in both 
Pretreatment with GH resulted in a higher car&ac groups (Table 3). Central venous pressure was sig- 
index (CI) at all stages of surgery (control: post-in- nificantly higher in the rhGH-treated group at the start 
duction 3 52 + 0.2 1/min; postclamp 3.1 + 0.3; post-un- of surgery (control. 8 3 cm H20; preop and postop GH: 
clamp 2.96+0.33; preop and postop GH: post- 13.5+0.93cm H20 (p = 0.0001)), but this increase did 
induction 4.2 + 0.54; postclamp 3.27_+ 0.3; post-un- not persist (Table 3). There was a statistically significant 
clamp 3.94_+ 0.44) (Fig. 4). This difference was not difference in rate pressure product between the two 
statistically significant (p = 0.067) and may be due to groups at two time points (control: post-unclamp 
sample size However, the increase m cardiac index 9279 + 519; end of surgery 8855 + 463; preop and postop 
Table 2. Intraoperative details of 25 patients who underwent surgery. 
Control Preop and postop 
(combined control and rhGH 
postop GH groups) 
Duration of anaesthesia (r in) 251 ± 21 266 + 24 
Duration of surgery (rain) 178 ± 19 176 ±22 
Cross-clamp time (mm) 77 ± 9 89 ± 15 
Blood loss (mls) 1882±321 1718_+375 
Intravenous fluids (ml) 6468 _+ 577 6428 ± 967 
Crystalloid (ml) 2875 ± 304 3357 ± 520 
Colloid (ml) 2468 ± 349 1928 ± 229 
Blood transfusion (ml) 1100 + 170 1142 ± 540 
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2.5 - second patient (control) died on day 16 postoperatively 
from respiratory failure secondary to a brain stem 
2 - infarct. Two patients in the control group developed 
prolonged ilues postoperatively; another patient de- 
1 5 veloped congestive cardiac failure and right lower 
lobe pneumonia which prolonged hospital±sat±on. O e 
1 patient in the control group developed a trash foot 
lntraoperatively necessitating embolectomy and 
fasciotomy. Two patients in the pre and postop GH 
0 5 group developed congestive cardiac failure and pneu- 
monia. Another patient in this group developed a
0 postoperative pulmonary embolus 10 days after dis- 
charge from hospital and required rehospitalisation 
-0 5 - for antlcoagulation. There was no significant difference 
between groups for duration of ventilation or total 
-1 I I I I I I stay in the intensive care unit. 
s~ ~ ~*~ Patients treated with GH had a shorter total hospital 
<:,~'~ ~'~ ~;'~ ~'~' ×~ "4~ 9~"~" stay (13+2 days)compared to the control group 
~°~ ~*~" ~ °4~'- 4>~ (17 + 3) but this was not statistically significant (Table 
%me 5) Patients pretreated with GH required significantly 
greater doses of diuretics (frusemide) in the post- 
Fig. 4. Cardiac index measured mtraoperatlvely m patmnts reated operative period (preop and post GH 82.5 + 38.81 mg; 
with placebo preoperatively (control) and patmnts reated with GH postop GH 43.5 + 21.37 mg, p = 0.05). One patient in 
preoperatively and postoperatively (preop and postop) Car&ac 
index is shown on the y-axis as htres Time points at whlch cardiac the pre and post GH groups developed hyperglycemia 
output was measured is shown on the x-axis Key as for Fig 3 '~p = in the immediate postoperative p riod requiring treat- 
0 067 vs control (ANOVA) ment with oral hypoglycemic agents. On follow-up 6 
GH: post-unclamp 13 953+1014 p=0.0002 vs. control; weeks later blood sugar levels had normalised, al- 
end of surgery: 8855 ± 463) (p = 0.039 vs. control), though the patient required continuing treatment with 
There was a significant difference in mean arterial oral hypoglycemic agents. 
blood pressure at one time point only, following aortic 
unclamping. Patients treated with GH preoperatively 
maintained a significantly higher MABP following Discussion 
clamp removal than controls (control. 91 ±4 mmHg; 
preop and postop GH: 110±3mmHg) (p=0.01) (Fig. 
5). Preoperative cardiac status and myocardial reserve 
exerts a profound effect on the haemodynamic re- 
sponse to aortic cross-clamping and unclamping. Aor- 
Gas exchange tic cross-clamping is associated with a decrease in 
cardiac index and an increase in peripheral vascular 
resistance. 3 Increased peripheral vascular resistance There were no significant differences between groups 
in pOd, CvO2 or CaO2. Oxygen delivery (DO2) and results in elevated left ventricular wall tension con- 
consumption (VO2) was significantly higher in the GH- tnbuting to decreased ventricular function and myo- 
treated group at only one time point (VO2: preclamp: cardial ischaemia due to reduced subendocardial 
control 2.03±5ml/min/kg; preop and postop GH" perfusion. After release of the aortic clamp, declamp 
20 79 ± 6.1 ml /min/kg (p = 0.046 vs. control); DO2: pre- hypotension may be avoided by maintaining a stable 
clamp: control 69.8 + 11 ml/min/kg; preop and postop cardiac output through volume loading and main- 
GH: 111.3 ± 14 ml/min/kg) (p = 0.05) (Table 4). tenance of a high pulmonary capillary wedge pressure. 
The results of this study demonstrate that ad- 
ministration of GH before aortic surgery results in 
Chnwal outcome increased lntraoperative cardiac output, maintained 
throughout surgery. This increase was not statistically 
There were two deaths in this series. One patient significant, but this is probably due to small patmnt 
(postop GH)died 42 days postoperatively from sep- numbers in the study. We feel, however, that the 
ticaemia following wound infection and dehiscence. A increases in cardmc output in the GH-treated group 
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120 - are of c l in ical  s igni f icance.  Pat ients  p re t reated  w i th  GH 
• exh ib i ted  a s ign i f i cant ly  less pronounced hypotens ive  
response  to aort ic unc lamping .  This  may imp ly  im-  
110-  p roved  card iovascu lar  per fo rmance  in  the face of a 
sudden decrease in  systemic  vascu lar  res istance.  
P rev ious  s tu&es  have  conf i rmed a benef ic ia l  role 
100 for GH on  cardiac funct ion .  12'13 In  an imals ,  v isceral  
o rgans  inc lud ing  the hear t  shr ink  after hypo-  
physectomy and  increase w i th  growth  hormone ad-  
90 min is t ra t ion .  14Implantat ion  of GH-secret ing  tumours  
in  exper imenta l  an ima ls  has  been  shown to sig- 
n i f i cant ly  increase cardiac output  and  myocard ia l  con-  
8o tracti l ity. 1~ IGF-1 also increases  cardiac pro te in  
synthes is  and  the synthes is  of card iac  contract i le  p ro -  
teins.  16'17 Recent  exper imenta l  s tud ies  have  dem-  
70 I I I I I I E 
onst ra ted  a benef ic ia l  effect for IGF-1 in  the 
4,~,~o~°*" ~ ÷4~ ~ ÷4"~ ~ ~ ,~,~'~ 9 ÷'~" dys funct iona l  hear t  in  evo lv ing  myocard ia l  in-  
-~*~" ~¢-J q,~"4~ o~,"*~ ~,~'~ farct ion. ~8 Anabo l i c  effects of GH on  the human myo-  
q~ card ium have  prev ious ly  been  demonst ra ted .  At  least 
Txme 50% of acromegal ic  pat ients  have  ev idence  of left 
vent r i cu la r  hyper t rophy  and  growth  hormone de- 
Fig. 4. Mean arterial blood pressure (MABP) measured mtra- 
operatively m control and pretreated patients (preop and postop) f ic iency is assoc iated w i th  impa i red  card iac  funct ion  
Time points at which measurements were taken are shown on the both  at rest and  in  response  to exercise. 19 Ca ldah l  et 
x-ax~s Data is presented as mean_+ s e M. Key as for Fig 3 *p =0 01 al. have  shown an  18% increase in  left ventncu lar  mass  
vs control unclamp 
in  GH def ic ient  pat ients  t reated w i th  GH.  2° 
Table 4. Intraoperative gas exchange measured intraoperatively in the two experimental groups (control=combined control and 
postop rhGH: preop and postop rhGH = those patients treated with rhGH preoperatively and postoperatively) (1 = post-induction; 2 = 
preclamp; 3 = postclamp; 4 = pre-unclamp; 5 = post-unclamp; 6 = end surgery). 
Time Point 1 2 3 4 5 6 
Hb (g/dl) 
Control 1102_+07 91+06 932_+04 89_+05 97_+05 1015_+06 
Preop and postop 1045+09 98_+6 92_+05 95_+15 101-+07 107-+05 
Hct (%) 
Control 33 _+ 1 8 27_+ 1 7 28 + 1 2 27_+ 1 2 29 _+ 1 35 30 + 1 6 
Preop and postop 31 -t- 2 5 29 _+ 1 8 27 + 1 5 28 -+ 4 3 30 _+ 2 2 31 -+ 1 3 
pO2 (kPase) 
Control 27 _+ 4 8 23 -+ 2 8 20 _+ 0 94 23 _+ 1 45 26 1 _+ 1 7 26 5 _+ 2 4 
Preop and postop 22 _+ 2 2 14 _+ 2 7 11 4 _+ 2 16 _+ 2 3 19 2 _+ 1 8 18 9 _+ 4 2 
02 Sat (%) 
Control 0991_+0002 099_+0001 099_+0002 0991_+0001 099_+0.001 099_+0002 
Preop and postop 0 987 _+ 0 003 0 958 _+ 0 006* 0 94 _+ 0 021" 0 972 _+ 0 007* 0 982 _+ 0 003* 0 969 _+ 0 008* 
CaO2 
Control 15_+09 125_+082 128_+06 1237_+06 133_+07 139_+08 
Preop and postop 143_+12 131_+08 1204+08 13-+21 138-+1 144-Z-06 
CvO2 
Control 11 9-+0 7 12 2_+0 7 11 _+0 5 9 9 _+0 82 10 6 +0 8 10 7_+0 6 
Preop and postop 117_+12 103_+17 105_+09 114_+203 1242_+05 116_+12 
DO2 (ml/mm/kg) 
Control 74 _+ 8 70 _+ 11 70 + 6 70 _+ 9 86 _+ 6 83 _+ 7 
Preop and postop 84 _+ 13 111 _+ 14" 77_+ 10 67 _+ 5 104 _+ 19 93 -+ 10 
VO2 (ml/mm/kg) 
Control 14_+3 2+5 16_+2 16_+2 17_+4 21 -+5 
Preop and postop 15 _+ 2 21 _+ 6 × 9 _+ 5 13 _+ 4 17 _+ 5 17 + 5 
• p<0 05 versus control, Hb = haemoglobm, Hct = haematocnt, pO2 = arterial oxygenation, 02 sat = oxygen saturation, CaO2 = arterial oxygen 
content; CvO2 = venous oxygen content, DO2 = oxygen dehvery, VO2 = oxygen consumption 
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Table 5. Outcome following surgery in the three groups. 
Control Preop and postop 
(combined control and 
postop rgGH) 
Mortahty 2 0 
Morbidity 4 3 
Duratmn of ventilation (h) 18.5 + 4 2 27 7-- 12 
ICU stay (h) 76 + 7 118 + 31 
Total hospltai stay (days) 17 ± 3 13 ± 2 
More recent studies using mvaslve monitoring tech- mediated through epatic and local generation of in- 
niques have shown that GH administration leads to sulin-like growth factor (IGF-1). Circulating IGF-1 con- 
improved left ventricular function in patients with centratlons are diminished uring malnutrition, liver 
idiopathic cardiomyopathy using low dose rhGH failure, diabetes melhtus and catabolic illness. There- 
(14 IU/week) for 3 months. 2~'22 Stroke volume was fore, the patients' underlymg nutritional status, the 
increased while heart rate remained unchanged re- quantity and quahty of nutrient retake, and the under- 
sulting in increased cardiac output at rest. This im- lying illnesses and their seventy influence the patients' 
provement in cardiac function correlated with a endogenous IGF-1 response to GH treatment. In the 
significant increase m left ventricular mass and wall present study IGF-1 concentrations increased slg- 
thickness which returned to pretreatment values once nificantly In the group treated with GH prior to sur- 
GH treatment was discontmued. These findings of gery This increase persisted into the postoperative 
increased cardiac output, though similar to ours, sug- period. A less marked increase was seen in the group 
gest that high dose GH administered for long periods given GH in the postoperative period only. This dif- 
does not act through the same mechanism as low dose ference in IGF-1 response to administered GH has 
GH given for shorter periods, been previously described by Mijaaland et al. in piglets 
Several mechanisms have been proposed to explain given GH for 3 days before operation or given GH on 
the role of GH m improving cardiac function. As in the morning of surgery only. 24 The authors hy- 
the current study, administration of GH induces a pothesised that the difference in postoperative r - 
sigmficant mcrease in heart rate thereby raising cardiac sponse was due to the lack of nutrition in the 
output. Previous authors have shown improved stroke postoperative period which down-regulated GH re- 
volume in GH-treated patients. 1°'I2 However, in our ceptors in the liver and that IGF-1 concentrations were 
study stroke volume remained unchanged. Another further decreased by the surgical injury. 
factor which may contribute to increased cardiac out- Treatment with GH did not have a sigmficant impact 
put is the increase in blood volume and resultant on duration of postoperative ventilation. However, 
increased preload. Sodium retention and an increase patients pretreated with GH had a shorter hospital 
in extracellular volume are well recognised with GH stay but this was not statistically significant. The small 
treatment. "-3 Evidence for this phenomenon from the number of patients in this study precludes definitive 
current study included the increased perioperative comment on the effect of GH on postoperative mor- 
central venous pressure and increased requirements bidity. 
for diuretics in the postoperative period in the pre- It is clear from this pilot study that GH could 
treated GH group. The finding of increased cardiac have an important role in improving perioperative 
output in the current study in association with an cardiopulmonary function m patients undergoing 
increase in heart rate must be interpreted with caution, major surgical procedures. This is the first clinical 
Patients undergoing aortic aneurysm repair often ex- study to examine specifically the effect of GH on 
hibit evidence of concurrent coronary artery disease, cardiac function in a group of surgical patients where 
Imposition of an increased metabolic rate on such perioperatlve myocardial performance is critical to 
patients could theoretically aggravate xisting myo- outcome and adds to the growing awareness of the 
cardial ischaemla. Although no patient m the current effects of growth hormone on myocardial function. 
study developed clinical evidence of myocardial isch- However, larger studies are reqmred in order to ex- 
aemia, close monitoring of patients undergoing GH amine more fully the impact of GH treatment m intra- 
treatment is recommended, operative cardiac function in major vascular 
The growth promotmg actions of GH are largely operations. 
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